SOBRE ESTE EPISÓDIO
This week, we sit down with Jean-Baptiste Morlot of Deep Life, who makes the case that the drug discovery field has been asking the wrong thing of its AI models. Correlation-based machine learning can find patterns, but it can't tell you why a cell is sick or what it would take to make it healthy again. Jean-Baptiste walks us through how single-cell sequencing unlocked the data volume needed to train something far more ambitious: a causal world model of cellular biology that learns the underlying rules of disease rather than memorizing them.
We get into how Deep Life's TwinCell platform works, why most virtual cell benchmarks are quietly inflated by popularity bias, and what it means to build an interpretable AI that a biologist can trust.
Inglês
Estados Unidos da América
TRANSCRIÇÃO 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
PESQUISAR EPISÓDIOS PASSADOS
Pesquisar episódios anteriores de From Models to Medicine.
OUTROS EPISÓDIOS NESTE PODCAST
In this episode of From Models to Medicine, we sit down with Lavanya Anandan, Head of External Innovation, West Coast at CSL, whose path from bench scientist to Merck Group platform builder to UCSF Innovation Venture startup advisor gives her a rare view of where AI in drug discovery is delivering …
In this episode of From Models to Medicine, we sit down with Sarah Daniels, an environmental health researcher, who makes the argument that the chemicals making us sick might also be our best clues for building better drugs. She traces that idea from a 1976 discovery about dioxins all the way to an…
For this episode, we sit down with Banishree Saha, Global Biomarkers Lead at Takeda, who has worked in fields such as academic liver biology to translational biomarker work, over the course of her 20-year career. She walks us through what biomarkers really are, how flow cytometry went from single-c…
We chat with Karl Moritz, CEO of Reliant AI, now part of Cohere, whose career took him from NLP research to McKinsey to building AI infrastructure for drug development. Karl reminds us that clinical trial success rates have been stuck years, and the golden age of AI-powered target discovery isn't f…
In this episode, we sit down with Chris Nelson, an mRNA scientist at nCode Bio whose career has taken him from building blood transfusion matching tests now used by the NHS, to cancer genomics at Personalis, to the frontier of mRNA sequence design. Chris breaks down why the untranslated regions of …
Aviso: O podcast e a arte incorporada nesta página são de KAMI Think Tank, que é propriedade de seu proprietário e não é afiliado ou endossado por Listen Notes, Inc.
EDITAR
Obrigado por ajudar a manter a base de dados dos podcasts atualizada.
